S'abonner

The role of the small airways in the clinical expression of asthma in adults - 03/02/12

Doi : 10.1016/j.jaci.2011.11.017 
Claude S. Farah, MBBS a, b, c, , Gregory G. King, MBChB, PhD a, b, c, d, Nathan J. Brown, PhD a, b, c, Sue R. Downie, PhD a, b, c, Jessica A. Kermode, BSc (Hons1) a, b, c, Kate M. Hardaker, BSc a, b, c, Matthew J. Peters, MD b, e, Norbert Berend, MD a, b, c, Cheryl M. Salome, PhD a, b, c
a Woolcock Institute of Medical Research, Glebe, Australia 
b Sydney Medical School, University of Sydney, Sydney, Australia 
c Cooperative Research Centre for Asthma and Airways, Glebe, Australia 
d Department of Respiratory Medicine, Royal North Shore Hospital, St Leonards, Australia 
e Department of Respiratory Medicine, Concord Hospital, Concord, Australia 

Corresponding author: Claude S. Farah, MBBS, Airway Physiology Group, Woolcock Institute of Medical Research, PO Box M77, Missenden Rd, NSW, 2050, Australia.

Abstract

Background

The clinical relevance of increased ventilation heterogeneity, a marker of small-airways disease, in asthmatic patients is unclear. Ventilation heterogeneity is an independent determinant of airway hyperresponsiveness (AHR), improves with bronchodilators and inhaled corticosteroids (ICSs), and worsens during exacerbations, but its relationship to asthma control is unknown.

Objective

We sought to determine the association between ventilation heterogeneity and current asthma control before and after ICS treatment.

Methods

Adult subjects with asthma had lung function and asthma control (5-item Asthma Control Questionnaire [ACQ-5 score] ≥1.5 = poorly controlled, ACQ-5 score ≤0.75 = well controlled) measured at baseline. A subgroup with AHR had repeat measurements after 3 months of high-dose ICS treatment. The indices of ventilation heterogeneity in the regions of the lung where gas transport occurs predominantly through convection (ventilation heterogeneity in convection-dependent airways [Scond]) and through diffusion (ventilation heterogeneity in diffusion-dependent airways [Sacin]) were derived by using the multiple-breath nitrogen washout technique.

Results

At baseline (n = 105), subjects with poorly controlled asthma had worse FEV1, fraction of exhaled nitric oxide measured at 200 mL/s (Feno), Scond, and Sacin values. In the treatment group (n = 50) spirometric, Feno, residual volume (RV)/total lung capacity (TLC), AHR, and Scond values significantly improved. Asthma control also improved (mean ACQ-5 score, 1.3-0.7; P < .0001). The change in ACQ-5 score correlated with changes in Feno (rs = 0.31, P = .03), Sacin (rs = 0.32, P = .02), and Scond (rs = 0.41, P = .003) values. The independent predictors of a change in asthma control were changes in Scond and Sacin values (model r2 = 0.20, P = .005).

Conclusions

Current asthma control is associated with markers of small-airways disease. Improvements in ventilation heterogeneity with anti-inflammatory therapy are associated with improvements in symptoms. Sensitive measures of small-airway function might be useful in monitoring the response to therapy in asthmatic subjects.

Le texte complet de cet article est disponible en PDF.

Key words : Ventilation heterogeneity, small airways, asthma control, symptoms, inflammation, asthma, adults

Abbreviations used : ACQ-5, AHR, BDP-HFA, BMI, Feno, FVC, ICS, LABA, MBNW, RV, Sacin, Scond, TLC


Plan


 Supported by research grants from the National Health and Medical Research Council (NHMRC) of Australia and the Cooperative Research Centre for Asthma and Airways (CRCAA). Pharmaxis Ltd provided the mannitol kits for the bronchial challenge.
 Disclosure of potential conflict of interest: C. S. Farah has received honoraria from AstraZeneca, GlaxoSmithKline, and Novartis. G. G. King has received research support from the Cooperative Research Centre for Asthma, the National Health and Medical Research Council, and GlaxoSmithKline and has provided legal consultation/expert witness testimony for GlaxoSmithKline, AstraZeneca, and Boehringer Ingelheim. C. M. Salome has received research support from the Cooperative Research Centre for Asthma and Airways, the National Health and Medical Research Council of Australia, and GlaxoSmithKline. The rest of the authors declare that they have no relevant conflicts of interest.


© 2011  American Academy of Allergy, Asthma & Immunology. Publié par Elsevier Masson SAS. Tous droits réservés.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer
Export

    Export citations

  • Fichier

  • Contenu

Vol 129 - N° 2

P. 381 - février 2012 Retour au numéro
Article précédent Article précédent
  • Interaction between filaggrin null mutations and tobacco smoking in relation to asthma
  • Nikolaj Drimer Berg, Lise Lotte N. Husemoen, Betina Heinsbæk Thuesen, Lars-Georg Hersoug, Jesper Elberling, Jacob Pontoppidan Thyssen, Berit Christina Carlsen, Jeanne Duus Johansen, Torkil Menné, Klaus Bønnelykke, Steen Stender, Michael Meldgaard, Pal Bela Szecsi, Allan Linneberg
| Article suivant Article suivant
  • Airway TGF-β1 and oxidant stress in children with severe asthma: Association with airflow limitation
  • Sheena D. Brown, Katherine M. Baxter, Susan T. Stephenson, Annette M. Esper, Lou Ann S. Brown, Anne M. Fitzpatrick

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Déjà abonné à cette revue ?

Mon compte


Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.


Tout le contenu de ce site: Copyright © 2024 Elsevier, ses concédants de licence et ses contributeurs. Tout les droits sont réservés, y compris ceux relatifs à l'exploration de textes et de données, a la formation en IA et aux technologies similaires. Pour tout contenu en libre accès, les conditions de licence Creative Commons s'appliquent.